Acrivon Therapeutics, Inc. · NASDAQ:ACRV

Acrivon Therapeutics — Corporate Update (February 2026)

13 slides from Acrivon Therapeutics's corporate update, Feb 27, 2026

  1. Slide 1: KOL Panel Discussion: ACR-368 Endometrial Cancer Trial

    KOL PANEL DISCUSSION ACR-368 ENDOMETRIAL CANCER TRIAL February 27, 2026 Exhibit 99.1

  2. Slide 2: Forward-looking statements

    Forward-looking statements Certain information contained in this presentation and related webcast includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding our future results of operations or financial condition, business strategy and pl

  3. Slide 3: Today's agenda

    Today’s agenda Welcome Adam Levy, Ph.D., M.B.A., CFO Introduction Peter Blume-Jensen, M.D., Ph.D., CEO ACR-368 Clinical Data Overview Brian Slomovitz, M.D. Q&A and Discussion Moderator: Mansoor Raza Mirza, M.D., CMO KOL Panelists: Ramez Eskander, M.D. Robert Coleman, M.D. Domenica Lorusso, M.D., Ph.

  4. Slide 4: Today's Participants

    Today’s Participants Robert Coleman, M.D. GOG Partners, Special Advisor to the President; GOG Foundation, Vice President; Texas Oncology, US Oncology Network; CMO, Vaniam group Brian Slomovitz, M.D. Member of the Board of Directors, GOG Foundation and the Uterine Cancer Lead, GOG Partners; Director

  5. Slide 5: Clinical activity of ACR-368 in endometrial carcinoma selected by OncoSignature

    CLINICAL ACTIVITY OF ACR-368 IN PATIENTS WITH ENDOMETRIAL CARCINOMA PROSPECTIVELY SELECTED BY ONCOSIGNATURE A PHASE 2 STUDY - ACR-368-201/GOG3082 (NCT05548296) Panagiotis Konstantinopoulos1, Mihae Song2, Ramez N Eskander3, Daniela Matei4, Ira Winer5, William H Bradley6, Lindsay Brubaker7, Michael Gu

  6. Slide 6: BM-Stratified Cohorts with Prospective Response Prediction

    BM-Stratified Cohorts with Prospective Response Prediction Subjects with high-grade EC ≤3 lines of prior therapy Background, Study Rationale & Design ACR-368-201/GOG-3082 presented by Panagiotis Konstantinopoulos The ACR-368 OncoSignature™ is a tumor agnostic, functional Biomarker (BM) test designed

  7. Slide 7: Subject Demographics

    ACR-368-201/GOG-3082 presented by Panagiotis Konstantinopoulos Subject Demographics Arm 1 (BM+) N = 40 Arm 2 (BM-) N = 48 Median Age (range) 66.0 (40, 77) 66.0 (49, 80) Race, n (%) White 29 (72.5) 29 (60.4) Black/African American 6 (15) 10 (20.8) Asian 1 (2.5) 4 (8.3) American Indian or Alaska Nativ

  8. Slide 8: Significant Response in Arm 1 (BM+) ITT Population Treated with ACR-368

    Significant Response in Arm 1 (BM+) ITT Population Treated with ACR-368 ACR-368-201/GOG-3082 presented by Panagiotis Konstantinopoulos * Best of BICR and/or PI # Unconfirmed PR Non QC’ed data based on EDC data extract as of 12/04/2025 # # ORR = 39% (95% CI, 24 - 56) n = 31 DCR: 80.6%, CBR (16 weeks)

  9. Slide 9: Better ORR Observed in Subjects with ≤2 Prior Lines of Therapy

    # # # Better ORR Observed in Subjects with ≤2 Prior lines of Therapy ACR-368-201/GOG-3082 presented by Panagiotis Konstantinopoulos n = 25 n = 35 ORR = 26% (95% CI, 14 - 42) ORR = 44% (95% CI, 27 - 63) Arm 1 (BM+) ACR-368 ARM 2 (BM-) ACR-368 + ULDG BOR by RECIST 1.1 on study treatment* * Best of BIC

  10. Slide 10: Significant ORR in Serous All-Comer Population with ≤2 Prior Lines

    Significant ORR in Serous All-Comer Population with ≤ 2 Prior Lines of Therapy ACR-368-201/GOG-3082 presented by Panagiotis Konstantinopoulos # # # n = 23 n = 37 Serous (≤ 2 Prior Lines) Non-Serous (≤ 2 Prior Lines) ORR = 22% (95% CI, 11 - 37) ORR = 52% (95% CI, 33 - 71) DCR: 74%, CBR (16 weeks): 65

  11. Slide 11: Favorable Safety Profile

    Favorable Safety Profile ACR-368-201/GOG-3082 presented by Panagiotis Konstantinopoulos Treatment-Related Adverse Events N = number of subjects (%) Arm 1 (ACR-368) N=40 Grades 3/4 Arm 2 (ACR-368 + ULDG) N=48 Grades 3/4 Thrombocytopenia 9 (22) 17 (34) Anemia 11 (27) 22 (46) Leukopenia 6 (15) 11 (23)

  12. Slide 12: Conclusions

    Conclusions ACR-368-201/GOG-3082 presented by Panagiotis Konstantinopoulos Subjects relapsed after prior platinum-based chemotherapy and one prior line of anti-PD-(L)1 therapy Arm 1 BM+ N=71 ACR-368 Arm 2 BM- N= up to ~150 ACR-368 with ULDG sensitization Biopsy-Independent Serous Cohort (US + EU) Su

  13. Slide 13: Serous endometrial cancer - a significant unmet need

    Serous endometrial cancer - a significant unmet need Disproportionate Mortality Accounts for ~40% of all endometrial cancer deaths.5 Limited Effective Treatment Options Only moderate benefit from immunotherapy Chemotherapy responses short-lived. Rapid resistance, early recurrence. HER2-targeting ben

Acrivon Therapeutics — Corporate Update (February 2026) on 6ix